Trafficking of δ-opioid receptors and other G-protein-coupled receptors: implications for pain and analgesia

Trends in Pharmacological Sciences

Volumn 28, Issue 1, 2007, Pages 23-31

  Cahill, Catherine M ^a   Holdridge, Sarah V ^a   Morinville, Anne ^b  

^a QUEEN S UNIVERSITY   (Canada)

^b ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID B RECEPTOR; ANALGESIC AGENT; DELTA OPIATE RECEPTOR; ENKEPHALIN[2 DEXTRO ALANINE 5 DEXTRO LEUCINE]; G PROTEIN COUPLED RECEPTOR; MU OPIATE RECEPTOR; OPIATE; OPIATE ANTAGONIST; RECEPTOR ACTIVITY MODIFYING PROTEIN 1; RECEPTOR ACTIVITY MODIFYING PROTEIN 2;

ALLODYNIA; ANALGESIA; ANTIDIURESIS; ANTINOCICEPTION; CELL SURFACE; CHRONIC PAIN; CONFORMATIONAL TRANSITION; COST BENEFIT ANALYSIS; DRUG POTENCY; ELECTRON MICROSCOPY; ENDOPLASMIC RETICULUM; GOLGI COMPLEX; HUMAN; HYPERALGESIA; NERVE CELL PLASTICITY; NONHUMAN; PAIN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW; SPINAL GANGLION;

ANALGESIA; ANIMALS; CELL MEMBRANE; HUMANS; PAIN; PROTEIN TRANSPORT; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, OPIOID, DELTA;

EID: 33846029187     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2006.11.003     Document Type: Review

References (97)

1. Perez D.M. Polymorphic G-protein-coupled receptors and associated diseases. Receptors Channels 8 (2002) 57-64
2. Pierce K.L., et al. Seven-transmembrane receptors. Nat. Rev. Mol. Cell Biol. 3 (2002) 639-650
3. Ahmad S., and Dray A. Novel G protein-coupled receptors as pain targets. Curr. Opin. Investig. Drugs 5 (2004) 67-70
4. Lembo P.M., et al. Proenkephalin A gene products activate a new family of sensory neuron-specific GPCRs. Nat. Neurosci. 5 (2002) 201-209
5. Ferguson S.S. Evolving concepts in G protein-coupled receptor endocytosis: the role in receptor desensitization and signaling. Pharmacol. Rev. 53 (2001) 1-24
6. McDonald P.H., and Lefkowitz R.J. Beta-arrestins: new roles in regulating heptahelical receptors' functions. Cell. Signal. 13 (2001) 683-689
7. Drake M.T., et al. Trafficking of G protein-coupled receptors. Circ. Res. 99 (2006) 570-582
8. Pierce K.L., and Lefkowitz R.J. Classical and new roles of beta-arrestins in the regulation of G-protein-coupled receptors. Nat. Rev. Neurosci. 2 (2001) 727-733
9. Ferguson S.S., et al. Molecular mechanisms of G protein-coupled receptor desensitization and resensitization. Life Sci. 62 (1998) 1561-1565
10. Claing A., et al. Endocytosis of G protein-coupled receptors: roles of G protein-coupled receptor kinases and beta-arrestin proteins. Prog. Neurobiol. 66 (2002) 61-79
11. Harter C., and Wieland F. The secretory pathway: mechanisms of protein sorting and transport. Biochim. Biophys. Acta 1286 (1996) 75-93
12. Blobel G. Protein targeting. Biosci. Rep. 20 (2000) 303-344
13. Morello J.P., et al. Pharmacological chaperones: a new twist on receptor folding. Trends Pharmacol. Sci. 21 (2000) 466-469
14. Brady A.E., and Limbird L.E. G protein coupled receptor interacting proteins: emerging roles in localization and signal transduction. Cell. Signal. 14 (2002) 297-309
15. Tan C.M., et al. Membrane trafficking of G protein-coupled receptors. Annu. Rev. Pharmacol. Toxicol. 44 (2004) 559-609
16. Prinster S.C., et al. Heterodimerization of G protein-coupled receptors: specificity and functional significance. Pharmacol. Rev. 57 (2005) 289-329
17. Foord S.M., and Marshall F.H. RAMPs: accessory proteins for seven transmembrane domain receptors. Trends Pharmacol. Sci. 20 (1999) 184-187
18. Burrows J.A., et al. Chemical chaperones mediate increased secretion of mutant alpha 1-antitrypsin (alpha 1-AT) Z: A potential pharmacological strategy for prevention of liver injury and emphysema in alpha 1-AT deficiency. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 1796-1801
19. Petaja-Repo U.E., et al. Ligands act as pharmacological chaperones and increase the efficiency of δ opioid receptor maturation. EMBO J. 21 (2002) 1628-1637
20. Powell K.J., et al. Paradoxical effects of the opioid antagonist naltrexone on morphine analgesia, tolerance, and reward in rats. J. Pharmacol. Exp. Ther. 300 (2002) 588-596
21. Brismar H., et al. Dopamine-induced recruitment of dopamine D1 receptors to the plasma membrane. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 5573-5578
22. Holtbäck U., et al. Receptor recruitment: a mechanism for interactions between G protein-coupled receptors. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 7271-7275
23. Duvernay M.T., et al. The regulatory mechanisms of export trafficking of G protein-coupled receptors. Cell. Signal. 17 (2005) 1457-1465
24. Rapaka R.S., and Porreca F. Development of δ opioid peptides as nonaddicting analgesics. Pharm. Res. 8 (1991) 1-8
25. Contet C., et al. μ Opioid receptor: a gateway to drug addiction. Curr. Opin. Neurobiol. 14 (2004) 370-378
26. Mika J., et al. The role of δ-opioid receptor subtypes in neuropathic pain. Eur. J. Pharmacol. 415 (2001) 31-37
27. Kiritsy-Roy J.A., et al. Sympathoadrenal, cardiovascular and blood gas responses to highly selective μ and δ opioid peptides. J. Pharmacol. Exp. Ther. 251 (1989) 1096-1103
28. May C.N., et al. Differential cardiovascular and respiratory responses to central administration of selective opioid agonists in conscious rabbits: correlation with receptor distribution. Br. J. Pharmacol. 98 (1989) 903-913
29. Szeto H.H., et al. Respiratory depression after intravenous administration of δ-selective opioid peptide analogs. Peptides 20 (1999) 101-105
30. Sharif N.A., and Hughes J. Discrete mapping of brain μ and δ opioid receptors using selective peptides: quantitative autoradiography, species differences and comparison with kappa receptors. Peptides 10 (1989) 499-522
31. Dykstra L.A., et al. Antinociceptive effects of the selective δ opioid agonist SNC80 alone and in combination with μ opioids in the squirrel monkey titration procedure. Psychopharmacology (Berl.) 163 (2002) 420-429
32. Shook J.E., et al. Peptide opioid antagonist separates peripheral and central opioid antitransit effects. J. Pharmacol. Exp. Ther. 243 (1987) 492-500
33. Tavani A., et al. Role of peripheral mu, delta and kappa opioid receptors in opioid-induced inhibition of gastrointestinal transit in rats. J. Pharmacol. Exp. Ther. 254 (1990) 91-97
34. Stewart P.E., and Hammond D.L. Activation of spinal δ-1 or δ-2 opioid receptors reduces carrageenan-induced hyperalgesia in the rat. J. Pharmacol. Exp. Ther. 268 (1994) 701-708
35. Hurley R.W., and Hammond D.L. The analgesic effects of supraspinal μ and δ opioid receptor agonists are potentiated during persistent inflammation. J. Neurosci. 20 (2000) 1249-1259
36. Fraser G.L., et al. Antihyperalgesic effects of δ opioid agonists in a rat model of chronic inflammation. Br. J. Pharmacol. 129 (2000) 1668-1672
37. Qiu C., et al. Enhanced δ-opioid receptor-mediated antinociception in μ-opioid receptor-deficient mice. Eur. J. Pharmacol. 387 (2000) 163-169
38. Cahill C.M., et al. Up-regulation and trafficking of δ opioid receptor in a model of chronic inflammation: implications for pain control. Pain 101 (2003) 199-208
39. Nichols M.L., et al. Regulation of morphine antiallodynic efficacy by cholecystokinin in a model of neuropathic pain in rats. J. Pharmacol. Exp. Ther. 275 (1995) 1339-1345
40. Kabli, N. and Cahill, C.M. (2006) Anti-allodynic effects of peripheral δ opioid receptors in neuropathic pain. Pain (in press)
41. Brainin-Mattos J., et al. Cancer-related bone pain is attenuated by a systemically available δ-opioid receptor agonist. Pain 122 (2006) 174-181
42. Onofrio B.M., and Yaksh T.L. Intrathecal δ-receptor ligand produces analgesia in man. Lancet i (1983) 1386-1387
43. Arvidsson U., et al. δ-Opioid receptor immunoreactivity: distribution in brainstem and spinal cord, and relationship to biogenic amines and enkephalin. J. Neurosci. 15 (1995) 1215-1235
44. Cheng P.Y., et al. Dual ultrastructural immunocytochemical labeling of μ and δ opioid receptors in the superficial layers of the rat cervical spinal cord. Brain Res. 778 (1997) 367-380
45. Cheng P.Y., et al. Ultrastructural immunolabeling shows prominent presynaptic vesicular localization of δ-opioid receptor within both enkephalin- and nonenkephalin-containing axon terminals in the superficial layers of the rat cervical spinal cord. J. Neurosci. 15 (1995) 5976-5988
46. Cahill C.M., et al. Immunocytochemical distribution of δ opioid receptors in rat brain: antigen-specific sub-cellular compartmentalization. J. Comp. Neurol. 440 (2001) 65-84
47. Commons K.G., et al. Anatomical evidence for presynaptic modulation by the δ opioid receptor in the ventrolateral periaqueductal gray of the rat. J. Comp. Neurol. 430 (2001) 200-208
48. Kieffer B.L. Opioids: first lessons from knockout mice. Trends Pharmacol. Sci. 20 (1999) 19-26
49. Cahill C.M., et al. Prolonged morphine treatment targets δ opioid receptors to neuronal plasma membranes and enhances δ-mediated antinociception. J. Neurosci. 21 (2001) 7598-7607
50. Morinville A., et al. Morphine-induced changes in δ opioid receptor trafficking are linked to somatosensory processing in the rat spinal cord. J. Neurosci. 24 (2004) 5549-5559
51. Morinville A., et al. μ-Opioid receptor knockout prevents changes in δ-opioid receptor trafficking induced by chronic inflammatory pain. Pain 109 (2004) 266-273
52. Morinville A., et al. Regulation of δ-opioid receptor trafficking via μ-opioid receptor stimulation: Evidence from μ-opioid receptor knock-out mice. J. Neurosci. 23 (2003) 4888-4898
53. Lucido A.L., et al. Prolonged morphine treatment selectively increases membrane recruitment of δ-opioid receptors in mouse basal ganglia. J. Mol. Neurosci. 25 (2005) 207-214
54. Gendron L., et al. Morphine and pain-related stimuli enhance cell surface availability of somatic δ-opioid receptors in rat dorsal root ganglia. J. Neurosci. 26 (2006) 953-962
55. Ma J., et al. Emergence of functional δ-opioid receptors induced by long-term treatment with morphine. Mol. Pharmacol. 69 (2006) 1137-1145
56. Pradhan A.A., et al. Chronic morphine administration results in tolerance to δ opioid receptor-mediated antinociception. Neuroscience 141 (2006) 947-954
57. Bao L., et al. Activation of δ opioid receptors induces receptor insertion and neuropeptide secretion. Neuron 37 (2003) 121-133
58. Guan J.S., et al. Interaction with vesicle luminal protachykinin regulates surface expression of δ-opioid receptors and opioid analgesia. Cell 122 (2005) 619-631
59. Zhang X., et al. Role of delivery and trafficking of δ-opioid peptide receptors in opioid analgesia and tolerance. Trends Pharmacol. Sci. 27 (2006) 324-329
60. Hack S.P., et al. Induction of δ-opioid receptor function in the midbrain after chronic morphine treatment. J. Neurosci. 25 (2005) 3192-3198
61. Walwyn W., et al. Induction of δ opioid receptor function by up-regulation of membrane receptors in mouse primary afferent neurons. Mol. Pharmacol. 68 (2005) 1688-1698
62. Zhai R.G., et al. Assembling the presynaptic active zone: a characterization of an active zone precursor vesicle. Neuron 29 (2001) 131-143
63. Bramham C.R., and Sarvey J.M. Endogenous activation of μ and δ-1 opioid receptors is required for long-term potentiation induction in the lateral perforant path: dependence on GABAergic inhibition. J. Neurosci. 16 (1996) 8123-8131
64. BR2. Nature 396 (1998) 674-679
65. B-receptor subtypes assemble into functional heteromeric complexes. Nature 396 (1998) 683-687
66. B receptor. Nature 396 (1998) 679-682
67. B receptor function. Science 283 (1999) 74-77
68. Neugebauer V. Metabotropic glutamate receptors - important modulators of nociception and pain behavior. Pain 98 (2002) 1-8
69. Brakeman P.R., et al. Homer: a protein that selectively binds metabotropic glutamate receptors. Nature 386 (1997) 284-288
70. Roche K.W., et al. Homer 1b regulates the trafficking of group I metabotropic glutamate receptors. J. Biol. Chem. 274 (1999) 25953-25957
71. Ciruela F., et al. Homer-1c/Vesl-1L modulates the cell surface targeting of metabotropic glutamate receptor type 1α: evidence for an anchoring function. Mol. Cell. Neurosci. 15 (2000) 36-50
72. Ango F., et al. Agonist-independent activation of metabotropic glutamate receptors by the intracellular protein Homer. Nature 411 (2001) 962-965
73. 2+-independent signaling pathway to extracellular signal-regulated protein kinase by coactivation of NMDA receptors and metabotropic glutamate receptor 5 in neurons. J. Neurosci. 24 (2004) 10846-10857
74. Ji R.R., et al. Nociceptive-specific activation of ERK in spinal neurons contributes to pain hypersensitivity. Nat. Neurosci. 2 (1999) 1114-1119
75. Tappe A., et al. Synaptic scaffolding protein Homer1a protects against chronic inflammatory pain. Nat. Med. 12 (2006) 677-681
76. McLatchie L.M., et al. RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. Nature 393 (1998) 333-339
77. Chen C., et al. GEC1 interacts with the kappa opioid receptor and enhances expression of the receptor. J. Biol. Chem. 281 (2006) 7983-7993
78. Bernier V., et al. Pharmacological chaperones: potential treatment for conformational diseases. Trends Endocrinol. Metab. 15 (2004) 222-228
79. Edwards S.W., et al. Localization of G-protein-coupled receptors in health and disease. Trends Pharmacol. Sci. 21 (2000) 304-308
80. Magni G., et al. Suicidality in chronic abdominal pain: an analysis of the Hispanic Health and Nutrition Examination Survey (HHANES). Pain 76 (1998) 137-144
81. Banks S.M., and Kerns R.D. Explaining high rates of depression in chronic pain: a diathesis-stress framework. Psychol. Bull. 119 (1996) 95-110
82. Gilron I., et al. Neuropathic pain: a practical guide for the clinician. Can. Med. Assoc. J. 175 (2006) 265-275
83. Filliol D., et al. Mice deficient for δ- and μ-opioid receptors exhibit opposing alterations of emotional responses. Nat. Genet. 25 (2000) 195-200
84. Kastin A.J., et al. Enkephalin and other peptides reduce passiveness. Pharmacol. Biochem. Behav. 9 (1978) 515-519
85. Tejedor-Real P., et al. Implication of endogenous opioid system in the learned helplessness model of depression. Pharmacol. Biochem. Behav. 52 (1995) 145-152
86. Tejedor-Real P., et al. Involvement of δ-opioid receptors in the effects induced by endogenous enkephalins on learned helplessness model. Eur. J. Pharmacol. 354 (1998) 1-7
87. Torregrossa M.M., et al. Peptidic δ opioid receptor agonists produce antidepressant-like effects in the forced swim test and regulate BDNF mRNA expression in rats. Brain Res. 1069 (2006) 172-181
88. Broom D.C., et al. Nonpeptidic δ-opioid receptor agonists reduce immobility in the forced swim assay in rats. Neuropsychopharmacol. 26 (2002) 744-755
89. Jutkiewicz E.M., et al. δ-Opioid agonists: differential efficacy and potency of SNC80, its 3-OH (SNC86) and 3-desoxy (SNC162) derivatives in Sprague-Dawley rats. J. Pharmacol. Exp. Ther. 309 (2004) 173-181
90. Jutkiewicz E.M., et al. Behavioral and neurobiological effects of the enkephalinase inhibitor RB101 relative to its antidepressant effects. Eur. J. Pharmacol. 531 (2006) 151-159
91. Saitoh A., et al. Potential anxiolytic and antidepressant-like activities of SNC80, a selective δ-opioid agonist, in behavioral models of rodents. J. Pharmacol. Sci. 95 (2004) 374-380
92. Commons K.G. Translocation of presynaptic δ opioid receptors in the ventrolateral periaqueductal gray after swim stress. J. Comp. Neurol. 464 (2003) 197-207
93. Svenningsson P., et al. Alterations in 5-HT1B receptor function by p11 in depression-like states. Science 311 (2006) 77-80
94. Gomes I., et al. Heterodimerization of μ and δ opioid receptors: A role in opiate synergy. J. Neurosci. 20 (2000) RC110
95. Petaja-Repo U.E., et al. Distinct subcellular localization for constitutive and agonist-modulated palmitoylation of the human δ opioid receptor. J. Biol. Chem. 281 (2006) 15780-15789
96. Kim K.A., and von Zastrow M. Neurotrophin-regulated sorting of opioid receptors in the biosynthetic pathway of neurosecretory cells. J. Neurosci. 23 (2003) 2075-2085
97. Patwardhan A.M., et al. Bradykinin-induced functional competence and trafficking of the δ-opioid receptor in trigeminal nociceptors. J. Neurosci. 25 (2005) 8825-8832